Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

Originally published as JCO Early Release 10.1200/JCO.2008.18.9068 on May 26 2009

Journal of Clinical Oncology, Vol 27, No 21 (July 20), 2009: pp. 3437-3444
© 2009 American Society of Clinical Oncology.

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Google Scholar
Right arrow Articles by Pierce, B. L.
Right arrow Articles by Ulrich, C. M.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pierce, B. L.
Right arrow Articles by Ulrich, C. M.
Related Articles
Right arrowRelated Editorial
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Elevated Biomarkers of Inflammation Are Associated With Reduced Survival Among Breast Cancer Patients

Brandon L. Pierce, Rachel Ballard-Barbash, Leslie Bernstein, Richard N. Baumgartner, Marian L. Neuhouser, Mark H. Wener, Kathy B. Baumgartner, Frank D. Gilliland, Bess E. Sorensen, Anne McTiernan, Cornelia M. Ulrich

From the Cancer Prevention and Epidemiology Research Programs, Fred Hutchinson Cancer Research Center; Department of Epidemiology, Institute for Public Health Genetics, and Department of Laboratory Medicine, University of Washington, Seattle, WA; Applied Research Program, Division of Cancer Control and Population Sciences, National Cancer Institute, Bethesda, MD; Department of Cancer Etiology, City of Hope National Medical Center, Duarte; Department of Preventive Medicine, University of Southern California, Los Angeles, CA; and Department of Epidemiology and Population Health, University of Louisville, Louisville, KY.

Corresponding author: Cornelia M. Ulrich, MS, PhD, Fred Hutchinson Cancer Center, Cancer Prevention Research Program, 1100 Fairview Ave N, M4-B402, Seattle WA 98109-1024; e-mail: nulrich{at}fhcrc.org.

Purpose Chronic inflammation is believed to contribute to the development and progression of breast cancer. Systemic C-reactive protein (CRP) and serum amyloid A (SAA) are measures of low-grade chronic inflammation and potential predictors of cancer survival.

Patients and Methods We evaluated the relationship between circulating markers of inflammation and breast cancer survival using data from the Health, Eating, Activity, and Lifestyle (HEAL) Study (a multiethnic prospective cohort study of women diagnosed with stage 0 to IIIA breast cancer). Circulating concentrations of CRP and SAA were measured approximately 31 months after diagnosis and tested for associations with disease-free survival (approximately 4.1 years of follow-up) and overall survival (approximately 6.9 years of follow-up) in 734 disease-free breast cancer survivors. Cox proportional hazards models were used with adjustment for potential confounding factors to generate hazard ratios (HRs) and 95% CIs.

Results Elevated SAA and CRP were associated with reduced overall survival, regardless of adjustment for age, tumor stage, race, and body mass index (SAA P trend < .0001; CRP P trend = .002). The HRs for SAA and CRP tertiles suggested a threshold effect on survival, rather than a dose-response relationship (highest v lowest tertile: SAA HR = 3.15; 95% CI, 1.73 to 5.65; CRP HR = 2.27; 95% CI, 1.27 to 4.08). Associations were similar and still significant after adjusting for self-reported history of cardiovascular events and censoring cardiovascular disease deaths. Elevated CRP and SAA were also associated with reduced disease-free survival, although these associations were of borderline significance (SAA P trend = .04; CRP P trend = .07).

Conclusion Circulating SAA and CRP may be important prognostic markers for long-term survival in breast cancer patients, independent of race, tumor stage, and body mass index.

Supported by National Cancer Institute Grants No. N01-CN-75036-20, NO1-CN-05228, NO1-PC-67010, U54-CA116847, and R25-CA94880; National Institutes of Health Grant No. M01-RR-00037; University of New Mexico Grant No. NCRR M01-RR-0997; National Institute of Child Health and Human Development Grant No. N01-HD-3-3175; and California Department of Health Services Grant No. 050Q-8709-S1528.

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?

Related Editorial

  • Chronic Inflammation and Breast Cancer Recurrence
    Steven W. Cole
    JCO 2009 27: 3418-3419 [Full Text]


This article has been cited by other articles:


Home page
JCOHome page
S. W. Cole
Chronic Inflammation and Breast Cancer Recurrence
J. Clin. Oncol., July 20, 2009; 27(21): 3418 - 3419.
[Full Text] [PDF]



About
JCO
 Editorial
Roster
 Advertising
Information
 Librarians &
Institutions
 Rights &
Permissions
 PDA Services

Copyright © 2009 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online